GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » E10

Abeona Therapeutics (FRA:PCJ) E10 : €0.00 (As of Dec. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Abeona Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was €-0.134. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average E10 Growth Rate was 15.60% per year. During the past 5 years, the average E10 Growth Rate was 25.60% per year. During the past 10 years, the average E10 Growth Rate was 33.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Abeona Therapeutics was 51.70% per year. The lowest was 3.80% per year. And the median was 13.20% per year.

As of today (2025-03-21), Abeona Therapeutics's current stock price is €4.66. Abeona Therapeutics's E10 for the quarter that ended in Dec. 2024 was €0.00. Abeona Therapeutics's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Abeona Therapeutics was 0.19. The lowest was 0.11. And the median was 0.17.


Abeona Therapeutics E10 Historical Data

The historical data trend for Abeona Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics E10 Chart

Abeona Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -37.19 -156.30 -87.35 -105.64 -

Abeona Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -105.64 -108.38 -32.76 -18.59 -

Competitive Comparison of Abeona Therapeutics's E10

For the Biotechnology subindustry, Abeona Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Shiller PE Ratio falls into.



Abeona Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Abeona Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.134/133.1571*133.1571
=-0.134

Current CPI (Dec. 2024) = 133.1571.

Abeona Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201503 -2.310 99.621 -3.088
201506 -3.564 100.684 -4.713
201509 -4.232 100.392 -5.613
201512 -1.377 99.792 -1.837
201603 -3.817 100.470 -5.059
201606 -4.450 101.688 -5.827
201609 -1.782 101.861 -2.330
201612 -4.503 101.863 -5.886
201703 -3.039 102.862 -3.934
201706 -4.673 103.349 -6.021
201709 -2.727 104.136 -3.487
201712 -4.014 104.011 -5.139
201803 -4.460 105.290 -5.640
201806 -5.564 106.317 -6.969
201809 -7.285 106.507 -9.108
201812 -7.911 105.998 -9.938
201903 -8.629 107.251 -10.713
201906 -10.841 108.070 -13.358
201909 -7.945 108.329 -9.766
201912 -6.525 108.420 -8.014
202003 -11.765 108.902 -14.385
202006 -3.108 108.767 -3.805
202009 -1.698 109.815 -2.059
202012 -3.493 109.897 -4.232
202103 -3.570 111.754 -4.254
202106 -3.262 114.631 -3.789
202109 -1.530 115.734 -1.760
202112 -9.956 117.630 -11.270
202203 -3.450 121.301 -3.787
202206 -1.287 125.017 -1.371
202209 -1.010 125.227 -1.074
202212 -0.379 125.222 -0.403
202303 -0.504 127.348 -0.527
202306 -0.849 128.729 -0.878
202309 -0.450 129.860 -0.461
202312 -0.587 129.419 -0.604
202403 -1.067 131.776 -1.078
202406 -0.242 132.554 -0.243
202409 -0.568 133.029 -0.569
202412 -0.134 133.157 -0.134

Add all the adjusted EPS together and divide 10 will get our e10.


Abeona Therapeutics  (FRA:PCJ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Abeona Therapeutics was 0.19. The lowest was 0.11. And the median was 0.17.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Abeona Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics Business Description

Traded in Other Exchanges
Address
6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Abeona Therapeutics Headlines

No Headlines